Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 3, 1997, Pages 38-44

  Drusano, G L ^a   Craig, W A ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Time above MIC

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFIXIME; CEFMENOXIME; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ANIMAL MODEL; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CHOICE; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHARMACODYNAMICS; PRESCRIPTION; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; HUMANS; LACTAMS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 0030787835     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother 1996; 40: 2686-2690.
2. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
3. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25: 213-217.
4. Walker R, Andes D, Conkin R, Ebert S, Craig W. Pharmacodynamic activities of meropenem in an animal infection model. Program and Abstracts of the 34th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, p 147, Abstract A91, American Society of Microbiologists, Washington DC, 1994.
5. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in acute otitis media. Pediatr Infect Dis J 1996; 15 (Suppl. 3): 255-259.
6. Gerber AU. Role of pharmacokinetics on the outcome of infections. Scand J Infect Dis 1990; 74 (Suppl.): 147-154.
7. Craig WA. Postantibiotic effects and dosing of macrolides, azalides and streptogramins. In: Zinner S, Young L, Acar J, eds. New macrolides, azalides and streptogramins in clinical practice (ICMAS III) (in press).
8. Schentag JJ, Smith IL, Swanson DJ, et al. Role of individualization with cefmenoxime. Am J Med 1984; 77 (Suppl. 6a): 43-50.
9. Garrison MW, Malone CL, Eiland JE, Anderson DE. Utilizing an in vitro pharmacodynamic chamber model (PDCM) to assess the influence of pH on the activity of Augmentin (A), Glarithromycin (C), and Clarithromycin plus its 14-OH metabolite (C+OH), versus Haemophilus influenzae. Abstract 1216, European Congress of Clinical Microbiology and Infectious Diseases, 1995, Vienna.
10. Schito G-C, Mannelli S, Pesce A and the Alexander Project Group. Trends in the activity of macrolide and β-lactam antibiotics and resistance development. J Chemother 1997; 9 (suppl. 3): 18-28.
11. Poulsen RL, Knudsen JD, Petersen MB et al. In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities. APMIS 1996; 104: 227-235.